期刊
TRANSLATIONAL RESEARCH
卷 225, 期 -, 页码 33-53出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2020.06.012
关键词
-
资金
- National Heart, Lung and Blood Institute CLOT Consortium [U01 HL143402]
- North American Society on Thrombosis and Hemostasis/Hemostasis and Thrombosis Research Society research fellowship
- Sondra and Stephen Hardis Chair in Oncology Research
Cancer-associated thrombosis is a leading cause of non-cancer death in cancer patients and is comprised of both arterial and venous thromboembolism (VTE). There are multiple risk factors for developing VTE, including cancer type, stage, treatment, and other medical comorbidities, which suggests that the etiology of thrombosis is multifactorial. While cancer-associated thrombosis can be treated with anticoagulation, benefits of therapy must be balanced with the increased bleeding risks seen in patients with cancer. Although risk models exist for primary and recurrent VTE, additional predictors are needed to improve model performance and discrimination of high-risk patients. This review will outline the diverse mechanisms driving thrombosis in cancer patients, as well as provide an overview of biomarkers studied in thrombosis risk and important considerations when selecting candidate biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据